

DECLARATION OF JAY NADEL UNDER 37 C.F.R. § 1.132		
Address to: Commissioner for Patents Alexandria, VA 22313-1450	Attorney Docket Confirmation No.	UCSF-085 CON5 9049
	First Named Inventor	Jay A. Nadel
	Application Number	10/816,159
	Filing Date	March 31, 2004
	Group Art Unit	1635
	Examiner Name	J.J. Zara
	Title	<i>Preventing airway mucus production by administration of EGF-R antagonists</i>

Dear Sir:

1. I, Jay Nadel, declare and say I am a co-inventor of the claims of the above-identified patent application.
2. I have read the Office Action dated March 6, 2007 in this application and understand that the Examiner has rejected pending claims 26-36.
3. The data presented below show that a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor reduces mucin induction in human nasal polyp epithelial cells. Therefore, an EGFR antagonist can be used to treat nasal polyps.
4. We previously showed that human nasal polyp epithelium overexpresses mucins and EGFR. These data were included in Example 8 of the instant application.